

1 **Mechanical ventilation affects respiratory microbiome of COVID-19 patients and its**  
2 **interactions with the host**

3

4 Verónica Lloréns-Rico<sup>1,2</sup>, Ann C. Gregory<sup>1,2</sup>, Johan Van Weyenbergh<sup>3</sup>, Sander Jansen<sup>4</sup>,  
5 Tina Van Buyten<sup>4</sup>, Junbin Qian<sup>5,6</sup>, Marcos Braz<sup>3</sup>, Soraya Maria Menezes<sup>3</sup>, Pierre Van  
6 Mol<sup>5,6,7</sup>, Lore Vanderbeke<sup>8</sup>, Christophe Doods<sup>7,9</sup>, Jan Gunst<sup>10</sup>, Greet Hermans<sup>10</sup>,  
7 Philippe Meersseman<sup>11</sup>, CONTAGIOUS collaborators, Els Wauters<sup>7,9</sup>, Johan Neyts<sup>4</sup>,  
8 Diether Lambrechts<sup>5,6</sup>, Joost Wauters<sup>11,12</sup>, Jeroen Raes<sup>1,2,12,13</sup>

9

10 <sup>1</sup> Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology,  
11 Rega Institute, KU Leuven, Belgium

12 <sup>2</sup> Center for Microbiology, VIB, Leuven, Belgium

13 <sup>3</sup> Laboratory for Clinical and Evolutionary Virology, Department of Microbiology and  
14 Immunology, Rega Institute, KU Leuven, Belgium

15 <sup>4</sup> Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology  
16 and Transplantation, Rega Institute, KU Leuven, Belgium

17 <sup>5</sup> Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven,  
18 Belgium

19 <sup>6</sup> VIB Center for Cancer Biology, VIB, Leuven, Belgium

20 <sup>7</sup> Department of Pneumology, University Hospitals Leuven, Belgium

21 <sup>8</sup> Laboratory of Clinical Bacteriology and Mycology, Department of Microbiology,  
22 Immunology and Transplantation, KU Leuven, Belgium

23 <sup>9</sup> Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of  
24 Chronic Diseases and Metabolism, KU Leuven, Belgium

25 <sup>10</sup> Laboratory of Intensive Care Medicine, Department of Cellular and Molecular  
26 Medicine, KU Leuven, Belgium

27 <sup>11</sup> Laboratory for Clinical Infectious and Inflammatory Disorders, Department of  
28 Microbiology, Immunology and Transplantation, KU Leuven, Belgium

29 <sup>12</sup> These authors contributed equally

30 <sup>13</sup> Corresponding author: [jeroen.raes@kuleuven.vib.be](mailto:jeroen.raes@kuleuven.vib.be)

31

32 **Keywords:** COVID-19, SARS-CoV-2, respiratory microbiome, single-cell RNA-  
33 sequencing, host-microbiome interactions

34

35

36 **Abstract**

37

38 Understanding the pathology of COVID-19 is a global research priority. Early evidence  
39 suggests that the microbiome may be playing a role in disease progression, yet current  
40 studies report contradictory results. Here, we examine potential confounders in  
41 COVID-19 microbiome studies by analyzing the upper (n=58) and lower (n=35)  
42 respiratory tract microbiome in well-phenotyped COVID-19 patients and controls  
43 combining microbiome sequencing, viral load determination, and immunoprofiling. We  
44 found that time in the intensive care unit and the type of oxygen support explained  
45 the most variation within the upper respiratory tract microbiome, dwarfing (non-  
46 significant) effects from viral load, disease severity, and immune status. Specifically,  
47 mechanical ventilation was linked to altered community structure, lower species- and  
48 higher strain-level diversity, and significant shifts in oral taxa previously associated  
49 with COVID-19. Single-cell transcriptomic analysis of the lower respiratory tract of  
50 ventilated COVID-19 patients identified increased oral microbiota compared to  
51 controls. These oral microbiota were found physically associated with proinflammatory  
52 immune cells, which showed higher levels of inflammatory markers. Overall, our  
53 findings suggest confounders are driving contradictory results in current COVID-19  
54 microbiome studies and careful attention needs to be paid to ICU stay and type of  
55 oxygen support, as bacteria favored in these conditions may contribute to the  
56 inflammatory phenotypes observed in severe COVID-19 patients.

57

58 **Introduction**

59

60 COVID-19, a novel coronavirus disease classified as a pandemic by the World Health  
61 Organization, has caused over 40 million reported cases and 1 million deaths  
62 worldwide to date. Infection by its causative agent, the novel coronavirus SARS-CoV-2,  
63 results in a wide range of clinical manifestations: it is estimated that around 80% of

64 infected individuals are asymptomatic or present only mild respiratory and/or  
65 gastrointestinal symptoms, while the remaining 20% develop acute respiratory distress  
66 syndrome requiring hospitalization and oxygen support and, of those, 25% of cases  
67 necessitate critical care. Despite a concerted global research effort, many questions  
68 remain about the full spectrum of the disease severity. Independent studies from  
69 different countries, however, agree that age and sex are the major risk factors for  
70 disease severity and patient death<sup>1-3</sup>, as well as type 2 diabetes and obesity<sup>4,5</sup>. Other  
71 risk factors for critical condition and death are viral load of the patient upon hospital  
72 admission<sup>6-8</sup> and the specific immune response to infection, with manifestation of a  
73 “cytokine storm” in critical patients characterized by increased levels of pro-  
74 inflammatory cytokines and chemokines, sustaining a disproportionate immune  
75 response that may ultimately cause organ failure<sup>9-11</sup>.

76

77 Despite its close interplay with the immune system and its known associations with  
78 host health, little is known about the role of the respiratory microbiota in modulating  
79 COVID-19 disease severity, or its potential as a prognostic marker<sup>12</sup>. Previous studies  
80 exploring other pulmonary disorders have shown that lung microbiota may exacerbate  
81 their symptoms and contribute to their severity<sup>13</sup>, potentially through direct crosstalk  
82 with the immune system and/or due to bacteremia and secondary infections<sup>14</sup>. Few  
83 studies of the respiratory microbiome in COVID-19 have revealed elevated levels of  
84 opportunistic pathogenic bacteria<sup>15-17</sup>. However, reports on bacterial diversity are  
85 contradictory. While some studies report a low microbial diversity in COVID-19  
86 patients<sup>15,18</sup> that rebounds following recovery<sup>16</sup>, others show an increased diversity in  
87 the COVID-19 associated microbiota<sup>17</sup>. These conflicting results could be due to  
88 differences in sampling location (upper or lower respiratory tract), severity of the  
89 patients, disease stage, or other confounders. While these early findings already  
90 suggest that the lung microbiome could be exacerbating or mitigating COVID-19  
91 progression, exact mechanisms are yet to be elucidated. Therefore, an urgent need  
92 exists for studies identifying and tackling confounders in order to discern true signals  
93 from noise.

94

95 To identify potential associations between COVID-19 severity and evolution and the  
96 upper and lower respiratory tract microbiota, we used nasopharyngeal swabs and  
97 bronchoalveolar lavage (BAL) samples, respectively. For the upper respiratory tract, we  
98 longitudinally profiled the nasopharyngeal microbiome of 58 COVID-19 patients during  
99 intensive care unit (ICU) treatment and after discharge to a classical hospital ward  
100 following clinical improvement, in conjunction with viral load determination and  
101 nCounter immune profiling. For the lower respiratory tract, we analyzed microbial  
102 signals in cross-sectional single-cell RNA-seq data from of bronchoalveolar lavage (BAL)  
103 samples of 22 COVID-19 patients and 13 pneumonitis controls with negative COVID-19  
104 qRT-PCR, obtained from the same hospital. The integration of these data enabled us to  
105 (1) identify potential confounders of COVID-19 microbiome associations, (2) explore  
106 how microbial diversity evolves throughout hospitalization, (3) study microbe-host cell  
107 interaction and (4) substantiate a link between the respiratory microbiome and SARS-  
108 CoV-2 viral load as well as COVID-19 disease severity. Altogether, our results directly  
109 point to specific interactions between the microbiota and the immune cells, likely  
110 driven by clinical ventilation practices, which could potentially influence COVID-19  
111 disease progression and resolution.

112

## 113 **Results**

114

### 115 **The upper respiratory microbiota of COVID-19 patients**

116

117 We longitudinally profiled the upper respiratory microbiota of 58 patients diagnosed  
118 with COVID-19 based on a positive qRT-PCR test or a negative test with high clinical  
119 suspicion based on symptomatology and a chest CT-scan showing alveolar damage. All  
120 these patients were admitted and treated at UZ Leuven hospital. Patient demographics  
121 for this cohort are shown in Table 1.

122

123 In total, 112 nasopharyngeal swabs from these patients were processed (Figure 1a):  
124 the V4 region of the 16S rRNA gene amplified on extracted DNA using 515F and 806R  
125 primers, and sequenced on an Illumina MiSeq platform (see Methods). From the same  
126 swabs, RNA was extracted to determine SARS-CoV-2 viral loads and to estimate

127 immune cell populations of the host using nCounter (Methods). Of the 112 samples  
128 processed and sequenced, 101 yielded over 10,000 amplicon reads that could be  
129 assigned to bacteria at the genus level (Figure 1b; Methods). The microbiome of the  
130 entire cohort was dominated by the gram-positive genera *Staphylococcus* and  
131 *Corynebacterium*, typical from the nasal cavity and nasopharynx<sup>19</sup>.

132

### 133 **Bacterial alpha diversity is strongly associated with ICU stay length**

134

135 First, we determined genus-level alpha-diversity for the 101 samples with more than  
136 10,000 assigned reads, using Shannon Diversity index (see Methods; Supplementary  
137 Table 1). We observed that alpha diversity was not significantly correlated to SARS-  
138 CoV-2 viral load in nasopharyngeal swabs (Figure 1c). In contrast, we found the  
139 Shannon index to be significantly affected by the sampling moment (Kruskal-Wallis  
140 test, p-value = 0.0076; Figure 1d), with significant differences between swabs procured  
141 upon patient admission and later timepoints, suggesting an important effect of disease  
142 progression and/or treatment (i.e. due to antibiotics administered throughout ICU  
143 stay). We explored these differences further, and observed that Shannon Diversity  
144 index correlated negatively with the number of days spent in ICU at the moment of  
145 sampling, with longer ICU stays leading to a lower diversity (Supplementary Figure 1a;  
146  $\rho=-0.55$ , p-value= $4.4 \cdot 10^{-9}$ ). Furthermore, the observed decrease in diversity occurred  
147 mostly over the first 2 weeks in ICU (Supplementary Figure 1a). Other severity  
148 indicators, such as the patient clinical status (i.e. a qualitative metric used to classify  
149 patients into different levels of disease severity) or the type of oxygen support  
150 required at the moment of sampling, showed no association with the genus-level  
151 Shannon index (Supplementary Figure 1b,c). Therefore, the differences in diversity  
152 observed across samples were likely driven by the time spent in ICU, and not  
153 specifically by disease progression as other severity indicators were unaffected.

154

155 Since time in ICU had a major effect in alpha diversity, we explored whether it might  
156 be masking any effects of viral load, as SARS-CoV-2 load was not associated with the  
157 length of the ICU stay (Supplementary Figure 1d). When controlling for the time in ICU  
158 (see Methods), we observed that viral load was negatively associated with the

159 Shannon diversity index ( $\rho=-0.26$ ,  $p$ -value=0.0089; Supplementary Figure 1e). Other  
160 severity indicators such as the clinical status and the type of oxygen support were not  
161 correlated to diversity even after controlling for the confounding effect of ICU stay  
162 (Kruskal-Wallis test,  $p$ -value>0.05).

163

#### 164 **Microbiome composition variation is driven by the type of respiratory support**

165

166 We next explored potential associations between the upper respiratory genus-level  
167 microbiota composition and the extensive metadata collected in the study. In total, 70  
168 covariates related to patient anthropometrics, medication and clinical variables  
169 measured in the hospital and host cytokine expression measured in the swabs were  
170 tested (Supplementary Table 2). Individually, 19 of these covariates showed a  
171 significant correlation to microbiota composition (dbRDA,  $p$ -value<0.05;FDR<0.05;  
172 Figure 2a). These significant covariates were related to disease and measures of its  
173 severity, such as the clinical evaluation of the patient, the total length of the ICU stay,  
174 the number of days in ICU at the time of sampling, or the type of oxygen support  
175 needed by the patient. Surprisingly, the total SARS-CoV-2 viral load detected in the  
176 swabs was not significantly associated to microbiome composition variation  
177 (Supplementary Table 2).

178

179 Of the 19 significant covariates, only 2 accounted for 48.7% non-redundant variation in  
180 this dataset, with the rest holding redundant information. These were the patient ID,  
181 included due to the longitudinal sampling of patients, and confirming that intra-  
182 individual variation over time is smaller than patient inter-individual variation<sup>20</sup>, and  
183 the type of oxygen support received at the time of sampling (Figure 2a,b). Notably, the  
184 type of oxygen support discriminated samples based on ventilation type, with non-  
185 invasive ventilation samples (groups 1, 2 and 3) separating from samples from  
186 intubated patients (groups 4 to 7; PERMANOVA test,  $R^2=0.0642$ ,  $p$ -value=0.001).

187

188 To determine if oxygen support also impacted the microbiome at finer taxonomic  
189 resolution, we revisited alpha-diversity at species- and strain-level. We defined species  
190 as 97% identity 16S OTUs and strains per species as the clustered 16S sequences

191 within each OTU. The species and strain-level diversity per sample were calculated as  
192 the number of OTUs and as the mean of the number of strains from five randomly  
193 sampled OTU species sampled 1,000 times, respectively. Our analyses revealed both  
194 species- and strain-level diversity change with ventilation, even with non-invasive  
195 ventilation (e.g. BIPAP, CPAP). Across all samples we observed high species- and low  
196 strain-level diversity pre-ventilation, which reversed following any form of ventilation  
197 (Figure 2c; Wilcoxon test;  $p$ -values $<0.05$ , with the exception of type 7), with the  
198 exception of ventilation with inhaled nitric oxide. Further, Species- and strain-level  
199 diversity showed a strong inverse correlation (Figure 2d; Pearson's correlation,  $R^2 = -$   
200 0.92,  $p$ -value = 0.0035).

201  
202 Therefore, we evaluated which specific taxa were differentially abundant between  
203 samples from intubated and non-intubated patients. In total, 30 genera were more  
204 abundant in intubated samples, while 2 genera were more abundant in non-invasively  
205 ventilated patients ( $p$ -value $<0.05$ ; FDR $<0.05$ ; Figure 2e, Supplementary Figure 2;  
206 Supplementary Table 3). Some of these taxa are common oral microbiome  
207 commensals or opportunistic pathogens that had been repeatedly reported as more  
208 abundant in COVID-19 patients than in healthy controls, such as *Prevotella*, *Veillonella*,  
209 *Fusobacterium*, *Porphyromonas* or *Lactobacillus*<sup>15-17</sup>. Here, we reported higher  
210 abundance of these genera in intubated COVID-19 patients as compared to non-  
211 mechanically ventilated patients. This points at mechanical ventilation as a potential  
212 confounder of previous COVID-19 studies. Additionally, we found other taxa not  
213 previously reported in previous COVID-19 microbiome studies, such as *Mycoplasma* or  
214 *Megasphaera* (Figure 3c, Supplementary Figure 2), but previously associated to risk of  
215 ventilator-associated pneumonia<sup>21</sup>.

216  
217 By extracting the amplicon sequence variants (ASVs) corresponding to these  
218 differentially abundant genera (see Methods), some of these taxa could be narrowed  
219 down to the species level, confirming their origin as typically oral bacteria: for  
220 instance, *Prevotella* species included *P. oris*, *P. salivae*, *P. denticola*, *P. buccalis* and *P.*  
221 *oralis*. Within the *Mycoplasma* genus, ASVs were assigned to *Mycoplasma salivarium*  
222 among other species, an oral bacterium which has been previously associated to the

223 incidence of ventilator-associated pneumonia<sup>21</sup>. When controlling for ventilation type,  
224 no taxa were found associated to SARS-CoV-2 viral loads. These results show that  
225 further research with larger cohorts and controlling for the relevant confounders  
226 highlighted here, such as ventilation type or length of stay in ICU, will be needed to  
227 study the specific effect of the viral infection.

228

### 229 **Single-cell RNA-seq identifies oral commensals and opportunist pathogens in the** 230 **lower respiratory tract**

231

232 Next, we explored what the functional consequences of (ventilation-driven) lung  
233 microbiome disturbances could be. To do so, we screened single-cell RNA-seq data  
234 generated on BAL samples of 35 patients<sup>22</sup> to identify microbial reads. All patients in  
235 this cross-sectional cohort had clinical symptoms of pneumonia, 22 of them being  
236 diagnosed with COVID-19. The other 13 patients with non-COVID-19 pneumonia were  
237 hereafter referred to as controls (Table 1). Microbiome read screening of these  
238 samples revealed an average of 7,295.3 microbial reads per sample (ranging from 0 to  
239 74,226 reads, with only a single sample yielding zero microbial reads; Supplementary  
240 Figure 3).

241

242 Among the top taxa encountered in these patients, we found some similarities with  
243 the data obtained in nasopharyngeal swabs. The top 15 species detected include  
244 *Mycoplasma salivarium* as the dominating taxon in 5 COVID-19 patients in ICU, as well  
245 as different *Prevotella* members. Non-COVID-19 pneumonia patients in ward (i.e. non-  
246 intubated) harbored different microbes: 2 patients had a microbiome dominated by  
247 *Porphyromonas gingivalis*, while a single patient had a microbiome dominated by the  
248 fungus *Pneumocystis jirovecii*, a known pathogen causing pneumonia<sup>23</sup>.

249 Supplementary table 4 shows associations between organism abundances and specific  
250 patient metadata: disease, hospital stay and ventilation type. Multiple links with  
251 COVID-19 diagnosis were identified (Wilcoxon test, (noncorrected) p-value<0.05; see  
252 Methods) but due to the low sample number, none was significant after multiple-test  
253 correction. Additionally, as hospital stay (ICU or ward), type of oxygen support  
254 (invasive or non-invasive ventilation) and disease (COVID-19 or controls) were highly



255 correlated (Chi-squared test, p-value < 0.0001 for all three pairwise correlations), the  
256 effect of these three variables could not be disentangled.

257

258 **Bacteria in the lower respiratory tract associate to host cells from the innate immune**  
259 **system in COVID-19 patients**

260

261 Next, we took advantage of the single-cell barcoding and questioned whether the  
262 microbial cells that we identified were found in association with host cells, or  
263 contrarily, had unique barcodes suggesting a free-living state. In total, 29,886 unique  
264 barcodes were identified that matched a total of 46,151 microbial UMIs. The  
265 distribution of UMIs per barcode was asymmetrical, ranging from 1 to 201 and with  
266 88% of the barcodes having a single UMI. Additionally, 26,572 barcodes (89%) were  
267 associated to a single microbial species, the rest being associated to 2 species (8.8%) or  
268 more (2.2%).

269

270 Out of the total 29,886 microbial barcodes, only 2,108 were also assigned to host cells,  
271 suggesting that the bulk of bacteria found in BAL samples exist as free-living organisms  
272 or in bacterial biofilms. However, for those associated to host cells, the distribution  
273 across disease types was not random. We found that while 2.3% of the non-COVID-19  
274 patient cells were associated to bacterial cells, almost the double (4%) could be  
275 observed in COVID-19 patients (Figure 3a; Chi-squared test; p-value <  $2.2 \cdot 10^{-16}$ ).  
276 However, because COVID-19 diagnosis is highly correlated with intubation in this  
277 cohort, this effect could be due to higher intubation rates in COVID-19 patients. Within  
278 COVID-19 patients, we also evaluated the overlap between bacteria-associated host  
279 cells and cells with detected SARS-CoV-2 reads (Supplementary Table 5). Out of 1033  
280 host cells associated with bacteria in these patients and 343 cells with detected SARS-  
281 CoV-2 reads, only one cell was positive for both. A binomial test for independence of  
282 virus and bacteria detection in the same host cell, showed that the observed co-  
283 occurrence in one cell only was highly unlikely (p-value= $5.7 \cdot 10^{-4}$ ), therefore suggesting  
284 mutual exclusion of microbiome members and viruses in the same host immune cells.

285

286 We also explored whether host-associated bacterial reads would preferentially be  
287 linked with specific cell types, taking into account the varying frequencies of cell types  
288 in COVID-19 patients and controls (see Methods). Such a preferential association  
289 would suggest that these observations are biologically relevant and not an artifact of  
290 the single-cell sample and library preparation. Among control patients, cell types were  
291 similarly distributed in both groups (i.e. with and without bacteria), with only a  
292 preferential association of microbial cells with neutrophils (p-value =  $3.61 \cdot 10^{-12}$ ; Figure  
293 3b; Supplementary Figure 4). However, in COVID-19 patients, three cell types were  
294 significantly associated with bacteria: neutrophils (p-value <  $2.2 \cdot 10^{-16}$ ), monocytes ((p-  
295 value =  $4.82 \cdot 10^{-5}$ ) and monocyte-derived macrophages (p-value <  $2.2 \cdot 10^{-16}$ ; Figure 3b;  
296 Supplementary Figure 4). We also found that different bacteria associate with distinct  
297 host cells. For instance, in COVID-19 patients, bacteria from the *Mycoplasma* genus  
298 preferentially associated to monocyte-derived macrophages (p-value =  $2.28 \cdot 10^{-7}$ ),  
299 while *Rothia* (p-value =  $8.21 \cdot 10^{-4}$ ), *Enterobacter* (p-value =  $2.59 \cdot 10^{-5}$ ), or *Klebsiella* (p-  
300 value =  $3.12 \cdot 10^{-9}$ ) are enriched in monocytes (Figure 3c).

301  
302 Last, we investigated whether the associations of bacteria to host cells are linked to  
303 host cell expression. To do so, we assessed whether expression based cell subtype  
304 classification<sup>22</sup> for neutrophils, monocytes and macrophages showed non-random  
305 associations with bacteria across all samples in this cohort. Among the neutrophils, a  
306 subtype of inflammatory neutrophils characterized by expression of the calgranulin  
307 S100A12 was enriched in bacteria-associated cells (p-value  $7.18 \cdot 10^{-6}$ ; Figure 3d,e). This  
308 subset of cells was also found to be enriched in SARS-CoV-2 nucleocapsid gene reads<sup>22</sup>,  
309 suggesting that the same cell type responsible for defense against the virus would be  
310 responding to potentially invasive bacteria in the lung. This subgroup is characterized  
311 by the expression of the calprotectin subunits S100A8 and S100A9. It is known that  
312 S100A8/A9 heterodimer secretion is increased in infection-induced inflammation and  
313 has some antibacterial effects mediated by secretion of pro-inflammatory cytokines,  
314 release of reactive oxygen species and recruitment of other inflammatory cells, as well  
315 as chelation of  $Zn^{2+}$  necessary for bacterial enzymatic activity<sup>24</sup>. These mechanisms are  
316 mediated by binding of the S100A8/A9 dimer to TLR4 receptors to trigger the release  
317 of pro-inflammatory cytokines such as IL-6 and TNF- $\alpha$ , and thus may contribute to

318 sustain or exacerbate inflammation<sup>25</sup>. Therefore, the association with bacteria could,  
319 at least in part, explain the inflammatory phenotype of this neutrophil subset. To  
320 further examine this hypothesis, we explored differential gene expression between  
321 bacteria-associated and non-associated S100A12<sup>hi</sup> neutrophils (Supplementary Table  
322 6). Because association of these cells with SARS-CoV-2 and with bacteria was mutually  
323 exclusive, we also compared these changes with the ones triggered by the virus in  
324 neutrophils<sup>22</sup>. Within this subset, neutrophils with co-occurring bacteria showed  
325 significantly higher expression (Bonferroni-corrected p-value < 0.05) of pro-  
326 inflammatory genes, including the cytokine IL1B and some of its target genes (PTSG2),  
327 the transcription factors FOS and JUN, and several genes involved in degranulation  
328 (S100A9, FOLR3, HSPA1A, HSP90AA1, FCGR3B), (Supplementary Table 6). Among  
329 these, FOLR3, a gene encoding for a folate receptor, is found in neutrophil secretory  
330 granules and has antibacterial functions, by binding folates and thus depriving bacteria  
331 of these essential metabolites<sup>26</sup>. This response differed to that of virus-engulfing  
332 neutrophils in that IFN response genes are not distinctively upregulated by bacteria.

333

334 Regarding myeloid cells, both inflammatory IL1B<sup>hi</sup> monocytes (p-value =  $2 \cdot 10^{-16}$ ) as well  
335 as a mixed group of CCL2-expressing macrophages (p-value =  $5.38 \cdot 10^{-10}$ ) are enriched  
336 in bacteria-associated cells (Figure 3f). These inflammatory monocytes are believed to  
337 have an important role in the cytokine storm occurring in severe COVID-19 patients. In  
338 this case, further gene expression patterns were detected, specific for bacteria-  
339 associated cells: for CCL2<sup>hi</sup> macrophages, cells with co-occurring bacteria expressed  
340 higher levels of MHC genes of type I and II, suggesting a more active role of these cells  
341 in antigen presentation (Bonferroni-corrected p-value < 0.05; Figure 3f; Supplementary  
342 Table 6). A similar increase was also observed in monocytes, yet not significant  
343 (Supplementary Table 6), possibly due to the lower monocyte abundances in this  
344 dataset. Additionally, bacteria-associated macrophages express significantly higher  
345 levels of the calprotectin subunits S100A8/A9, similarly to neutrophils, as well as pro-  
346 inflammatory chemokines (such as CCL4, CXCL10 and CXCL1).

347

348 Altogether, our results suggest that the bacteria detected in these cell subsets via  
349 scRNA-seq analyses may be contributing to the inflammatory response observed in the  
350 host.

351

## 352 **Discussion**

353

354 Since the beginning of the COVID-19 pandemic, a massive global effort by the scientific  
355 community was undertaken to understand physiopathology of SARS-CoV-2 infection  
356 and risk factors affecting disease outcome. In this study, we explored the respiratory  
357 microbiota as a potential risk factor for disease severity, and we evaluated the upper  
358 and lower respiratory tract microbiota in COVID-19 patients throughout their  
359 hospitalization. We linked this data to viral load measurements and immunoprofiling  
360 results from nCounter and single-cell RNA sequencing data. To assess robustness of  
361 previously reported signals, we investigated the effect of potential confounders based  
362 on a broad panel of patient metadata variables.

363

364 We found that in the upper respiratory tract, while SARS-CoV-2 viral load has a weak  
365 negative association with bacterial biodiversity, a strong effect of severity indicators  
366 such as ICU stay was observed, with diversity decreasing throughout the length of the  
367 ICU period, a pattern reminiscent of that seen in other pulmonary conditions<sup>27,28</sup>.

368 This effect of ICU and/or ventilation on microbiome alpha diversity could potentially  
369 explain why previous studies on the microbiota of COVID-19 patients show conflicting  
370 results regarding diversity: some studies reported lower diversity in sputum or throat  
371 swab samples of COVID-19 patients<sup>15,16,18</sup> while others focusing on the lower  
372 respiratory microbiome using bronchoalveolar fluid samples, showed higher bacterial  
373 diversity in COVID-19 patients than in controls<sup>17</sup>. To further complicate matters, it  
374 cannot be excluded that sampling site or processing could also be potential  
375 confounders in these studies and/or reflect the different pathologies in the different  
376 areas of the respiratory tract.

377

378 We further found that between patient microbiome variation (as measured by genus-  
379 level microbial beta-diversity) was also affected by different severity indicators such as

380 the clinical status of the patient, or more importantly the type of oxygen support  
381 received, with intubated patients harboring a different microbiota than non-intubated  
382 patients. The impact of oxygen support was also reflected at the species- and strain-  
383 levels, with intubation causing a significant decrease and increase, respectively, in  
384 diversity. We hypothesize that the introduction of forced oxygen may drive the fast  
385 extinction of certain microbial species enabling the diversification of existing or newly  
386 colonizing species into new strains. Our results suggest that non-invasive ventilation  
387 (e.g. BIPAP, CPAP) can have microbial effects indicating that any form of ventilation  
388 may be a tipping point for microbial community differences.

389

390 Importantly, several of the taxa reported to change between intubated and non-  
391 intubated patients were reported to be linked to diagnosis in previous COVID-19  
392 microbiome studies<sup>15-17</sup>. In our study, no taxa were differentially abundant between  
393 COVID-19 positive and negative patients after controlling for patient intubation. This  
394 result strongly points at the possibility that intubation and mechanical ventilation are  
395 confounding previous results. Indeed, one study comparing COVID-19 patients with  
396 patients diagnosed of community-acquired pneumonia found no differences in  
397 respiratory microbiome composition between both groups of patients, but both  
398 groups did differ from healthy controls<sup>29</sup>. Together, these results indicate that patient  
399 intubation or even non-invasive ventilation are to be considered as important  
400 confounders when studying the upper respiratory microbiome, and we strongly  
401 suggest future COVID-19 microbiome studies should foresee and include strategies to  
402 account for this covariate. A recent study found a single ASV corresponding to the  
403 genus *Rothia* that was specific for SARS-CoV-2 patients after controlling for ICU-related  
404 confounders<sup>30</sup>.

405

406 To better understand the potential functional consequences of these procedures and  
407 linked microbial shifts, we also profiled the microbiome of the lower respiratory tract  
408 using single-cell data obtained from a cross-sectional cohort of patients derived from  
409 the same hospital. Our results show that 'standard' single-cell RNA-seq, even though  
410 not optimized for microbial detection and profiling, can identify bacteria alone or in  
411 association with specific human cells. Unfortunately, the low numbers of microbial

412 reads obtained in this cohort, together with the fact that ICU stay, COVID-19 diagnosis  
413 and intubation are highly correlated in this set of patients, only allow for a descriptive  
414 analysis of the results. In this cohort, we identified different oral commensals and  
415 opportunistic pathogens previously linked to COVID-19 patients in both groups of  
416 samples, thus pointing again at a potential ventilation-linked origin. More interestingly,  
417 we identified a subset of bacteria associated with host cells, more specifically with  
418 neutrophils, monocytes and macrophages. This enrichment shows that these bacteria  
419 are likely not random contaminants, from which an even distribution across cell types  
420 (i.e. considering cell type abundances) would be expected. The identity of these host  
421 cells suggests that bacteria could have been phagocytosed by these innate immune  
422 system cells, rather than be attached to the host cell surface. To the best of our  
423 knowledge, this is the first study linking interacting host cells and lung microbiome via  
424 high-throughput single-cell RNA-seq.

425

426 We find that host cells associated with bacteria, most of which are of oral origin,  
427 exhibit pro-inflammatory phenotypes as well as higher levels of MHC for antigen  
428 presentation. In this single-cell cohort it was observed that critical COVID-19 patients  
429 are characterized by an impaired monocyte to macrophage differentiation, resulting in  
430 an excess of pro-inflammatory monocytes, as well as by prolonged neutrophil  
431 inflammation<sup>22</sup>. Given that only these cell types are enriched in bacteria, we  
432 hypothesize that the respiratory (or ventilation-linked) microbiome may be playing a  
433 role in exacerbating COVID-19 progression in the lower respiratory tract. We verified  
434 that this response would likely be driven by bacteria and not SARS-CoV-2, which is also  
435 detected mostly in these cell types, as there is almost no overlap in detection of both  
436 virus and bacteria in the same cells. However, it must be noted that lack of detection  
437 does not completely rule out presence of virus and bacteria within these cells.  
438 Therefore, further research is required in order to confirm a causative role of the  
439 microbiota in this immune impairment characteristic of critical disease, and to reveal  
440 the specific mechanisms involved.

441

442 The presence of oral taxa in the lung microbiota is not unique of disease conditions. It  
443 is known that microaspiration, or the aspiration of aerosol droplets originated in the

444 oral cavity, occurs in healthy individuals and can serve as a route for lung colonization  
445 of oral commensals<sup>31</sup>. Such an increase of oral bacteria in the lower respiratory tract  
446 could be facilitated when critically ill patients –including but not limited to COVID-19–  
447 get intubated. Indeed, oral bacteria have been linked to ventilator-associated  
448 pneumonia<sup>32,33</sup>. It is yet to be elucidated whether COVID-19 physiopathology favors  
449 lung colonization by oral bacteria or if, in contrast, a lung microbiome previously  
450 colonized by oral microbes could also contribute to the disease. What is known is that  
451 an increase of oral bacteria in the lower respiratory tract can result in an increased  
452 inflammatory phenotype, even in healthy subjects<sup>34</sup>

453

## 454 **Conclusion**

455

456 Overall, this study provides a systematic analysis of potential confounders in COVID-19  
457 microbiome studies. We identified that ICU hospitalization and type of oxygen support  
458 had large impacts on the upper respiratory tract microbiome and have the potential to  
459 confound clinical microbiome studies. Among the different types of oxygen support we  
460 reported the largest shifts in microbial community structure between intubated and  
461 non-intubated patients. We found that oral microbiota was strongly enriched in the  
462 upper and lower respiratory tracts of intubated COVID-19 patients. Further, in the  
463 lower respiratory tract, microbes were strongly associated with specific pro-  
464 inflammatory immune cells. This information contributes to a collective body of  
465 literature on the pathology of COVID-19 and suggests that careful attention be paid to  
466 ICU stay and type of oxygen support when evaluating the role of the lung microbiome  
467 on COVID-19 disease progression.

468

## 469 **Methods**

470

### 471 **Study design and patient cohorts**

472

473 All experimental protocols and data analyses were approved by the Ethics Commission  
474 from the UZ Leuven Hospital, under the COntAGlous observational clinical trial (study  
475 number S63381). The study design is compliant with all relevant ethical regulations,

476 including the Declaration of Helsinki and in the GDPR. All participants gave their  
477 informed consent to participate in the study.

478

479 A total of 58 patients from the COntAGlouS observational trial were included as our  
480 upper respiratory tract cohort. All patients were admitted to the UZ Leuven hospital  
481 with a diagnostic of COVID-19. The disease was diagnosed based on a) a positive qRT-  
482 PCR test, performed on admission or previously on other hospitals, when patients  
483 were transferred from other medical facilities; or b) a chest CT-scan showing alveolar  
484 damage and clinical symptoms of the disease. All patients included in the study were  
485 admitted to ICU for a variable amount of time. Nasopharyngeal swabs were taken from  
486 these patients at different timepoints throughout ICU stay and after ICU discharge,  
487 during recovery in ward. A total of 74 swabs were processed for upper respiratory  
488 microbiome characterization (Figure 1a).

489

490 To extend our findings from the upper respiratory tract, we also profiled the lower  
491 respiratory tract microbiota in a different cohort<sup>22</sup> of 35 patients belonging to the  
492 same observational trial and also recruited at UZ Leuven hospital. This cross-sectional  
493 cohort is composed by 22 COVID-19 patients and 13 pneumonitis controls with  
494 negative qRT-PCR for SARS-CoV-2, with varying disease severity. Previous data from  
495 single-cell RNA-sequencing had been collected for this cohort<sup>22</sup>. We reanalyzed this  
496 single-cell dataset to profile the lower respiratory tract microbiota in these patients.

497

498

#### 499 **RNA/DNA extraction and sequencing**

500

501 Nucleic acid extraction from the swab samples was performed with AllPrep  
502 DNA/RNA/miRNA Universal kit (QIAGEN, catnr. 80224). Briefly, swabs from the  
503 potentially infectious samples were inactivated by adding 600µL RLT-plus lysis buffer.  
504 To increase bacterial cell lysis efficiency, glass beads and DX reagent (Pathogen Lysis  
505 Tubes, QIAGEN, catnr. 19091) were added to the lysis buffer, and samples were  
506 disrupted in a FastPrep-24<sup>TM</sup> instrument with the following program: 1-minute beating  
507 at 6.5m/sec, 1-minute incubation at 4°C, 1-minute beating at 6.5m/sec, 1-minute



508 incubation at 4°C. After lysis, the remaining extraction steps followed the  
509 recommended protocol from the manufacturer. DNA was eluted in 50µL EB buffer.  
510 Amplification of the V4 region of the 16S gene was done with primers 515F and 806R,  
511 using single multiplex identifiers and adaptors as previously described<sup>35</sup>. RNA was  
512 eluted in 30µL of nuclease-free water and used for SARS-CoV-2 viral load  
513 determination in the swabs as well as to measure inflammatory markers and cytokines  
514 and to estimate host cell populations via marker gene expression using nCounter. In  
515 brief, raw nCounter data were processed using nSolver 4.0 software (Nanostring),  
516 sequentially correcting three factors for each individual sample: technical variation  
517 between samples (using spiked positive control RNA), background correction (using  
518 spiked negative control RNA) and RNA content variation (using 15 housekeeping  
519 genes). We have previously validated nCounter digital transcriptomics for  
520 simultaneous quantification of host immune and viral transcripts<sup>36</sup>, including  
521 respiratory viruses in nasopharyngeal aspirates, even with low RNA yield<sup>37–39</sup>.

522  
523 DNA sequencing was performed on an Illumina MiSeq instrument, generating paired-  
524 end reads of 250 base pairs.

525  
526 For quality control, reads were demultiplexed with LotuS v1.565<sup>40</sup> and processed  
527 following the DADA2 microbiome pipeline using the R packages DADA2<sup>41</sup> and  
528 phyloseq<sup>42</sup>. Briefly, reads were filtered and trimmed using the parameters truncQ=11,  
529 truncLen=c(130,200), and trimLeft=c(30, 30) and then denoised. After removing  
530 chimeras, amplicon sequence variants (ASVs) table was constructed and taxonomy was  
531 assigned using the Ribosomal Database Project (RDP) classifier implemented in DADA2  
532 (RDP trainset 16/release 11.5). The abundance table was then corrected for copy  
533 number, rarefied to even sampling depth, and decontaminated. For decontamination,  
534 we used the prevalence-based contaminant identification method in the R package  
535 decontam<sup>43</sup>.

536

537 **16S statistical analysis**

538

539 All the analyses were performed using R v3.6.0 and the packages `vegan`<sup>44</sup>, `phyloseq`<sup>42</sup>,  
540 `CoDaSeq`<sup>45</sup>, `DESeq2`<sup>46</sup>, `Biostrings`<sup>47</sup>, `rstatix`<sup>48</sup> and `DECIPHER`<sup>49</sup>.

541

542 To analyze the 16S amplicon data, technical replicates were pooled and counts from  
543 technical replicates were added. For all the analyses using genus-level agglomerated  
544 data, only samples containing more than 10,000 reads assigned at the genus level  
545 were used (101 samples in total). Alpha-diversity was analyzed using Shannon's  
546 Diversity Index. Comparison of the alpha diversity values across different groups was  
547 performed using Wilcoxon signed-rank tests for 2-group comparisons, and Kruskal-  
548 Wallis tests for comparisons across multiple groups. In the latter case, pairwise  
549 comparisons (when applicable) were performed using Dunn post-hoc tests. To de-  
550 confound for the effect of the ICU length, we fitted a quadratic model between the  
551 days spent at ICU and the Shannon index using the `lm` function in R. The residuals of  
552 this model were used to test the association with the SARS-CoV-2 viral load.

553

554 Beta diversity analyses were performed using distance-based redundancy analyses  
555 (RDA), using Euclidean distances on CLR-transformed data. RDA analyses were  
556 performed using the `capscale` function from `vegan`. Non-redundant contribution to  
557 variation was calculated using the `ordiR2step` function from `vegan`, using only the  
558 variables that were significant individually in the RDA, and a null model without any  
559 explanatory variables. For these analyses, taxa with prevalence lower than 10% were  
560 excluded. Metadata variables containing dates, as well as non-informative metadata  
561 (containing a single non-NA value or unique for only one patient) were also excluded.

562

563 Differential taxa abundance analyses were performed using `DESeq2`'s likelihood ratio  
564 tests and controlling for potential confounders when indicated, including them in the  
565 null model. All statistical tests are two-sided, and when multiple tests were applied to  
566 the different features (e.g. the differential taxa abundances across two conditions) p-  
567 values were corrected for multiple testing using Benjamini-Hochberg's method.

568

569 In order to explore species-level and strain-level diversity, 16S sequences were first  
570 clustered into 97% nucleotide diversity operational taxonomic units (OTUs) using the R

571 packages Biostrings and DECIPHER. These OTUs were used to represent the species-  
572 level. The number of unique 16S sequences clustered within each OTU were used to  
573 represent the number of detectable strains per species. To calculate strain-level  
574 diversity per sample, the number of strains of 5 detected OTU species were randomly  
575 selected and averaged. This was repeated 1,000x and the average of the all 1,000  
576 subsamplings was used as the final strain-level diversity value for each sample, as  
577 previously described<sup>50</sup>. To account for uneven sampling assessing diversity differences  
578 based on different parameters, we randomly selected and averaged the species- and  
579 strain-level diversity of 5 samples per parameter. This was repeated 100x and the  
580 subsamplings were used to assess the significant differences between species- and  
581 strain-level diversity across the parameters. The average was of all 100 subsamplings  
582 was used to as the input for a Pearson's correlation between species- and strain-level  
583 diversity.

584

#### 585 **Identification of microbial reads in BAL scRNA-seq data**

586

587 Single-cell data was processed with an in-house pipeline to identify microbial reads.  
588 Only read 2, containing the information on the cDNA, was used. Trimmomatic<sup>51</sup> (v0.38)  
589 was used to remove trim low quality bases and discard short reads. Additionally,  
590 Prinseq++<sup>52</sup> (v1.2) was used to discard reads with low-complexity stretches. Following  
591 quality control, reads from human and potential sequencing artifacts (phage phiX174)  
592 were mapped with STAR<sup>53</sup> (v2.7.1) and discarded. The remaining reads were mapped  
593 against bacterial genomes using a 2-step approach: first, we scanned the reads using  
594 mash screen<sup>54</sup> (v2.0) against a custom database of 11685 microbial reference genomes  
595 including bacteria, archaea, fungi and viruses. Genomes likely to be present in the  
596 analyzed sample (selected using a threshold of at least two shared hashes from mash  
597 screen) were selected and reads were pseudoaligned to this subset of genomes using  
598 kallisto<sup>55</sup> (v0.44.0). To remove potential artifacts, two additional filters were applied:  
599 first, if less than 10 different functions were expressed from a given species, the  
600 species was discarded. Second, if one function accounted for more than 95% of the  
601 mapped reads of a given species, it was also discarded. These filters were aimed at

602 removing potential artifacts caused by contamination or errors in the genome  
603 assemblies used in our database.

604

605 Differences in lower respiratory tract microbial taxa between COVID-19 patients and  
606 controls, ICU and ward patients, and invasive and non-invasive ventilation types were  
607 calculated using Wilcoxon rank-sum tests on centered-log-ratio (CLR)-transformed  
608 data. Prior to CLR data transformation, we filtered the data using the CoDaSeq.filter  
609 function, to keep samples with more than 1,000 reads and taxa with a relative  
610 abundance above 0.1%. Zeros were imputed using the minimum proportional  
611 abundance detected for each taxon. This more lenient approach than the one used for  
612 16S data was chosen due to the low number of samples available and the reduced  
613 number of bacterial reads identified per sample.

614

615 Bacterial reads were assigned their specific barcodes and UMIs as follows: IDs from the  
616 mapped microbial reads were retrieved from the kallisto pseudobam output, and used  
617 to retrieve their specific barcodes and UMIs using the raw data files from read 1,  
618 assigning each barcode and UMI univocally to a microbial species and function.

619

## 620 **Direct associations between bacteria and host cells**

621

622 Host single-cell transcriptomics data was obtained from the Seurat<sup>56</sup> object after  
623 preprocessing and integrating the samples of the single-cell cohort, as described  
624 previously<sup>22</sup>. From the Seurat object, the metadata was extracted, including the  
625 information on patient group (COVID-19 or control) and severity of the disease  
626 (moderate or critical) as well as cell type and subtype annotation corresponding to  
627 each barcode. Enrichment of bacteria detected in patient groups or cell types was  
628 calculated using chi-squared tests, with effect sizes determined via the standardized  
629 residuals. Significance was assessed via post-hoc tests using the R package  
630 `chisq.posthoc.test`<sup>57</sup>.

631

632 For cell types showing an enrichment in associated bacteria, a new Seurat object was  
633 created by subsetting the specific cell type. Chi-squared tests were also used to

634 determine enrichment of bacteria-associated cell subtypes. Previous annotations of  
635 cell subtypes<sup>22</sup> were used to generate new clusters manually and identify marker  
636 genes for these subtypes, using the function findAllMarkers from Seurat. This function  
637 was also used to find differentially expressed genes between bacteria-associated and  
638 not-bacteria-associated host cells of each subtype. When using this function, reported  
639 adjusted p-values are calculated using Bonferroni correction by default.

640

## 641 **Figure legends**

642

643 **Figure 1. Sample overview and alpha diversity.** a) Longitudinal sampling of patients.  
644 Each line represents one patient. Yellow lines span the days spent in ward, while blue  
645 lines span the days spent in ICU. Red points mark hospital discharge dates. Crosses  
646 indicate the timepoints where swab samples were obtained for microbiome analyses. b)  
647 Top 15 most abundant genera in this cohort. Samples with > 10,000 reads assigned to  
648 microbial taxa at the genus level were stratified according to the sampling moment:  
649 upon admission, throughout the ICU stay or at ICU discharge/during treatment in  
650 ward. c) Correlation between the SARS-CoV-2 viral load and Shannon diversity index of  
651 all samples. The shaded area surrounding the trend line represents the 95%  
652 confidence interval. d) Shannon diversity index of all samples, stratified by the  
653 sampling moment: admission, throughout ICU stay or at ICU discharge/during  
654 treatment in ward. Boxplots span from the first until the third quartile of the data  
655 distribution, and the horizontal line indicates the median value of the data. The  
656 whiskers extend from the quartiles until the last data point within 1.5 times the  
657 interquartile range, with outliers beyond. Individual data points are also represented.

658

659 **Figure 2. Upper respiratory microbiome covariates in COVID-19.** a) Significant  
660 covariates explaining microbiota variation in the upper respiratory tract in this cohort.  
661 Individual covariates are listed on the y-axis, their color corresponds to the metadata  
662 category they belong to: technical data, disease-related, microbiological tests,  
663 comorbidities or host cell populations or gene expression, the latter measured with  
664 nCounter (see Methods). Darker colors refer to the individual variance explained by  
665 each of these covariates assuming independency, while lighter colors represent the

666 cumulative and non-redundant variance explained by incorporating each variable to a  
667 model using a stepwise RDA analysis. The black horizontal line separates those  
668 variables that are significant in the non-redundant analysis on top (Patient ID and  
669 oxygen support) from the non-significant ones. b) RDA ordination plot showing the  
670 first 2 constrained axes. Ordination is constrained by the two significant variables  
671 “Patient ID” and “Oxygen support”. Samples are depicted as points, whose color  
672 indicates the oxygen support type of the patient and whose shape indicates stay at  
673 ward or ICU (at the moment of sampling). Axes indicate the variance explained by the  
674 first two constrained components of the RDA analysis. c) Species- (left) and strain-level  
675 diversity (right) of the samples, stratified by oxygen support type. d) Pearson  
676 correlation between average species- and strain- level diversity for each of the oxygen  
677 support categories. e) Significant differences among oxygen support types.  
678 Differentially abundant taxa between invasive (red) and non-invasive (blue) ventilated  
679 sample. Only the top 10 most significant taxa are shown, as determined by their  
680 adjusted p-value. Boxplots span from the first until the third quartile of the data  
681 distribution, and the horizontal line indicates the median value of the data. The  
682 whiskers extend from the quartiles until the last data point within 1.5 times the  
683 interquartile range, with outliers beyond. Individual data points are also represented.  
684 Gray lines join samples pertaining to the same patient, taken at different time points.  
685

686 **Figure 3. Host single cells associated to the lower respiratory tract microbiota.** a)  
687 relative proportion of cells from negative and positive COVID-19 patients with (red  
688 color) and without (blue) associated bacteria. The p-value of a chi-squared test using  
689 the count data is shown on top of the panel. b) Cell types enriched in bacteria-  
690 associated cells. Barplots represent the proportion of cell types without (“No”) and  
691 with (“Yes”) bacteria in COVID-19 positive and negative patients. For each patient  
692 class, we tested for enrichment of bacteria-associated cells (“Yes”) across the different  
693 cell types, using the proportions of non-bacteria associated cells (“No”) as background.  
694 Asterisks mark the cell types with significant enrichment of bacteria. c) Bacterial  
695 genera preferentially associating to specific cell types. The heatmaps show the  
696 standardized residuals of a chi-squared test including all bacterial genera and the three  
697 host cell types enriched in bacteria, for controls (left) and COVID-19 positive patients

698 (right). Taxa with no significant associations with any of the cell types are not shown.  
699 Asterisks denote significant positive or negative associations: enrichments are shown  
700 in red; depletions are depicted in blue. d) Host cell subtypes associated with bacteria.  
701 The heatmap shows the standardized residuals of a chi-squared test including the  
702 subtypes of neutrophils, monocytes and monocyte-derived macrophages with  
703 associated bacteria, considering cells without bacteria as background. Asterisks denote  
704 significant positive or negative associations: enrichments are shown in red; depletions  
705 are depicted in blue. e) Marker genes detected for the 5 different subtypes of  
706 neutrophils. The heatmap also shows within-group differences between bacteria-  
707 associated and bacteria-non-associated cells. f) Myeloid cell functional gene set  
708 showing the expression of canonical pro-inflammatory, anti-inflammatory and MHC  
709 genes for the two subtypes of myeloid cells significantly associated with bacteria  
710 (CCL2<sup>hi</sup>-macrophages and IL1B<sup>hi</sup>-monocytes). The heatmap also shows within group  
711 differences between bacteria-associated and bacteria-non-associated cells. Statistically  
712 significant differences after multiple testing correction are marked with squares. For  
713 b)-d) asterisks denote significance as follows: \* = p-value  $\leq$  0.05; \*\* = p-value  $\leq$  0.01;  
714 \*\*\* = p-value  $\leq$  0.001; \*\*\*\* = p-value  $\leq$  0.0001.

715

716

## 717 **Supplementary Figure Legends**

718

719 **Supplementary Figure 1.** Alpha diversity in the upper respiratory tract. a) Correlation  
720 between number of days spent in ICU at the moment of sampling and Shannon  
721 diversity index. For samples taken after discharge to ward, the total number of days  
722 spent in ICU was used. Spearman correlation and p-value are indicated in the upper  
723 right corner of the panel. The shaded area surrounding the trend line represents the  
724 95% confidence interval. b) Shannon diversity of the samples, grouped by patient  
725 clinical status at the moment of sampling. The p-value of a Kruskal-Wallis test is shown  
726 in the upper right corner of the panel. c) Shannon diversity of the samples, grouped by  
727 type of oxygen support supplied to the patient at the moment of sampling. The p-value  
728 of a Kruskal-Wallis test is shown in the upper right corner of the panel. d) Correlation  
729 between the days spent in ICU at the moment of sampling and SARS-CoV-2 viral load

730 of the sample. For samples taken after discharge to ward, the total number of days  
731 spent in ICU was used. The shaded area surrounding the trend line represents the 95%  
732 confidence interval. e) Correlation between SARS-CoV-2 viral load and Shannon  
733 diversity index, after controlling for the time spent in ICU. The residuals of a quadratic  
734 fit between the Shannon diversity and the days in ICU were correlated to the SARS-  
735 CoV-2 viral loads measured in the samples. Spearman correlation and p-value are  
736 indicated in the upper right corner of the panel. The shaded area surrounding the  
737 trend line represents the 95% confidence interval. For b) and c), boxplots span from  
738 the first until the third quartile of the data distribution, and the horizontal line  
739 indicates the median value of the data. The whiskers extend from the quartiles until  
740 the last data point within 1.5 times the interquartile range, with outliers beyond.  
741 Individual data points are also represented.

742

743 **Supplementary Figure 2.** Differentially abundant taxa between oxygen support types.  
744 The 32 taxa whose abundance is significantly different between non-invasive and  
745 invasive ventilation are represented. Boxplots span from the first until the third  
746 quartile of the data distribution, and the horizontal line indicates the median value of  
747 the data. The whiskers extend from the quartiles until the last data point within 1.5  
748 times the interquartile range, with outliers beyond. Individual data points are also  
749 represented. Gray lines join samples pertaining to the same patient, taken at different  
750 time points. An asterisk next to the genera name indicates that the differences  
751 between ventilation type are also significant after controlling for patient ID.

752

753 **Supplementary Figure 3.** Absolute microbial read counts in single-cell RNA-seq data  
754 from BAL samples. The top 15 species detected in our analyses are depicted. Samples  
755 are grouped by disease type (control for non-COVID-19 pneumonia patients, or COVID-  
756 19) and hospital stay (ICU or ward).

757

758 **Supplementary Figure 4.** Associations of specific cell types with bacteria, for COVID-19  
759 and control samples. The colors represent the strength of the association as the  
760 standardized residuals of a Chi-squared test. Red colors indicate a positive association  
761 (i.e. enrichment) of bacteria for each cell type. Blue colors indicate a negative



762 association (i.e. depletion) of bacteria for a given cell type. Asterisks denote  
763 significance as follows: \* = p-value  $\leq$  0.05; \*\* = p-value  $\leq$  0.01; \*\*\* = p-value  $\leq$  0.001;  
764 \*\*\*\* = p-value  $\leq$  0.0001.

765

#### 766 **Author contributions**

767 VLR, ACG, JW, JR designed the study. SJ, TVW, JN, CD, JG, GH, PM collected and  
768 processed the BAL samples. PVM and LV collected the clinical data. JW and EW  
769 collected the swabs. VLR, ACG and JVW processed the swabs. JVW, MB and SMM  
770 determined SARS-CoV-2 viral loads and host gene expression from swabs. DL and JQ  
771 generated the single-cell raw data as well as the processed gene-count matrix with  
772 annotations of cell types and subtypes. VLR and AGC analyzed the data. VLR, ACG and  
773 JR wrote the manuscript. All authors have read and approved the manuscript.

774

#### 775 **Acknowledgments**

776 This study has been supported by funding from the VIB Grand Challenges Program. VLR  
777 is supported by an FWO senior postdoctoral fellowship (12V9421N). ACG is supported  
778 by an EMBO postdoctoral fellowship (ALTF 349-2019). The Raes lab is supported by KU  
779 Leuven, the Rega institute and VIB.

780

#### 781 **Conflict of interest declaration**

782 The authors declare no competing interests.

783

#### 784 **CONTAGIOUS collaborators**

785 Yannick Van Herck, Alexander Wilmer, Michael Casaer, Stephen Rex, Nathalie Lorent,  
786 Jona Yserbyt, Dries Testelmans, Karin Thevissen.

787

#### 788 **Data availability**

789 Raw amplicon sequencing data that support the findings of this study have been  
790 deposited at the European Genome-phenome Archive (EGA), with accession no. XXX.

791

#### 792 **References**

793





794 1. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients

- 795 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**,  
796 1054–1062 (2020).
- 797 2. Grasselli, G. *et al.* Risk Factors Associated with Mortality among Patients with  
798 COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern. Med.* **180**,  
799 1345–1355 (2020).
- 800 3. Mikami, T. *et al.* Risk Factors for Mortality in Patients with COVID-19 in New  
801 York City. *J. Gen. Intern. Med.* 1–10 (2020). doi:10.1007/s11606-020-05983-z
- 802 4. Guo, W. *et al.* Diabetes is a risk factor for the progression and prognosis of  
803 <sc>COVID</sc> -19. *Diabetes. Metab. Res. Rev.* **36**, (2020).
- 804 5. Lighter, J. *et al.* Obesity in Patients Younger Than 60 Years Is a Risk Factor for  
805 COVID-19 Hospital Admission. *Clinical infectious diseases : an official publication*  
806 *of the Infectious Diseases Society of America* **71**, 896–897 (2020).
- 807 6. Yu, X. *et al.* SARS-CoV-2 viral load in sputum correlates with risk of COVID-19  
808 progression. *Crit. care* **24**, 170 (2020).
- 809 7. Magleby, R. *et al.* Impact of Severe Acute Respiratory Syndrome Coronavirus 2  
810 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With  
811 Coronavirus Disease 2019. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa851
- 812 8. Westblade, L. F. *et al.* SARS-CoV-2 Viral Load Predicts Mortality in Patients with  
813 and without Cancer Who Are Hospitalized with COVID-19. *Cancer Cell* (2020).  
814 doi:10.1016/j.ccell.2020.09.007
- 815 9. Coperchini, F., Chiovato, L., Croce, L., Magri, F. & Rotondi, M. The cytokine  
816 storm in COVID-19: An overview of the involvement of the  
817 chemokine/chemokine-receptor system. *Cytokine and Growth Factor Reviews*  
818 **53**, 25–32 (2020).
- 819 10. Henderson, L. A. *et al.* On the Alert for Cytokine Storm: Immunopathology in  
820 COVID-19. *Arthritis and Rheumatology* **72**, 1059–1063 (2020).
- 821 11. Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and  
822 immunosuppression. *The Lancet* **395**, 1033–1034 (2020).
- 823 12. Khatiwada, S. & Subedi, A. Lung microbiome and coronavirus disease 2019  
824 (COVID-19): Possible link and implications. *Human Microbiome Journal* **17**,  
825 100073 (2020).
- 826 13. Dickson, R. P., Martinez, F. J. & Huffnagle, G. B. The role of the microbiome in  
827 exacerbations of chronic lung diseases. *The Lancet* **384**, 691–702 (2014).
- 828 14. Huffnagle, G. B., Dickson, R. P. & Lukacs, N. W. The respiratory tract microbiome  
829 and lung inflammation: A two-way street. *Mucosal Immunology* **10**, 299–306  
830 (2017).
- 831 15. Zhang, H. *et al.* Metatranscriptomic Characterization of COVID-19 Identified A  
832 Host Transcriptional Classifier Associated With Immune Signaling. *Clin. Infect.*  
833 *Dis.* (2020). doi:10.1093/cid/ciaa663
- 834 16. Xu, R. *et al.* Temporal dynamics of human respiratory and gut microbiomes  
835 during the course of COVID. *medRxiv* 2020.07.21.20158758 (2020).  
836 doi:10.1101/2020.07.21.20158758
- 837 17. Han, Y., Jia, Z., Shi, J., Wang, W. & He, K. The active lung microbiota landscape of  
838 COVID-19 patients. *medRxiv* 2020.08.20.20144014 (2020).  
839 doi:10.1101/2020.08.20.20144014
- 840 18. Mostafa, H. H. *et al.* Metagenomic Next-Generation Sequencing of  
841 Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19





- 842 Patients Downloaded from. *MBio* **11**, (2020).
- 843 19. Ho Man, W., de Steenhuijsen Piters, W. A. & Bogaert, D. The microbiota of the  
844 respiratory tract: gatekeeper to respiratory health. (2017).  
845 doi:10.1038/nrmicro.2017.14
- 846 20. Whelan, F. J. *et al.* Longitudinal sampling of the lung microbiota in individuals  
847 with cystic fibrosis. *PLoS One* **12**, (2017).
- 848 21. Nolan, T. J. *et al.* Low-pathogenicity *Mycoplasma* spp. alter human monocyte  
849 and macrophage function and are highly prevalent among patients with  
850 ventilator-acquired pneumonia. *Thorax* **71**, 594–600 (2016).
- 851 22. Wauters, E. *et al.* Discriminating Mild from Critical COVID-19 by Innate and  
852 Adaptive Immune Single-cell Profiling of Bronchoalveolar Lavages. *Patrick*  
853 *Matthys* **9**, 14 (2020).
- 854 23. Harris, J. R., Balajee, S. A. & Park, B. J. Pneumocystis jirovecii pneumonia:  
855 Current knowledge and outstanding public health issues. *Current Fungal*  
856 *Infection Reports* **4**, 229–237 (2010).
- 857 24. Wang, S. *et al.* S100A8/A9 in inflammation. *Frontiers in Immunology* **9**, 1298  
858 (2018).
- 859 25. Coveney, A. P. *et al.* Myeloid-related protein 8 induces self-tolerance and cross-  
860 tolerance to bacterial infection via TLR4- and TLR2-mediated signal pathways.  
861 *Nat. Publ. Gr.* (2015). doi:10.1038/srep13694
- 862 26. Holm, J. & Hansen, S. I. Characterization of soluble folate receptors (folate  
863 binding proteins) in humans. Biological roles and clinical potentials in infection  
864 and malignancy. *Biochimica et Biophysica Acta - Proteins and Proteomics* **1868**,  
865 140466 (2020).
- 866 27. Zakharkina, T. *et al.* The dynamics of the pulmonary microbiome during  
867 mechanical ventilation in the intensive care unit and the association with  
868 occurrence of pneumonia. doi:10.1136/thoraxjnl-2016-209158
- 869 28. Schmitt, F. C. F. *et al.* Pulmonary microbiome patterns correlate with the course  
870 of disease in patients with sepsis-induced ARDS following major abdominal  
871 surgery. (2020). doi:10.1016/j.jhin.2020.04.028
- 872 29. Shen, Z. *et al.* Genomic Diversity of Severe Acute Respiratory Syndrome-  
873 Coronavirus 2 in Patients With Coronavirus Disease 2019. *Clinical infectious*  
874 *diseases : an official publication of the Infectious Diseases Society of America* **71**,  
875 713–720 (2020).
- 876 30. Marotz, C. *et al.* Title: Microbial context predicts SARS-CoV-2 prevalence in  
877 patients and the hospital built environment. *medRxiv* 2020.11.19.20234229  
878 (2020). doi:10.1101/2020.11.19.20234229
- 879 31. Bassis, C. M. *et al.* Analysis of the upper respiratory tract microbiotas as the  
880 source of the lung and gastric microbiotas in healthy individuals. *MBio* **6**, (2015).
- 881 32. Brennan, M. T. *et al.* The role of oral microbial colonization in ventilator-  
882 associated pneumonia. *Oral Surgery, Oral Med. Oral Pathol. Oral Radiol.*  
883 *Endodontology* **98**, 665–672 (2004).
- 884 33. Stonecypher, K. Ventilator-Associated Pneumonia: The Importance of Oral Care  
885 in Intubated Adults. *Crit. Care Nurs. Q.* **33**, 339–347 (2010).
- 886 34. Segal, L. N. *et al.* Enrichment of the lung microbiome with oral taxa is associated  
887 with lung inflammation of a Th17 phenotype. *Nat. Microbiol.* **1**, 1–11 (2016).
- 888 35. Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D.

- 889 Development of a dual-index sequencing strategy and curation pipeline for  
890 analyzing amplicon sequence data on the miseq illumina sequencing platform.  
891 *Appl. Environ. Microbiol.* **79**, 5112–5120 (2013).
- 892 36. Moens, B. *et al.* Simultaneous RNA quantification of human and retroviral  
893 genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines.  
894 *Viol. J.* **9**, 171 (2012).
- 895 37. Fukutani, K. F. *et al.* Pathogen transcriptional profile in nasopharyngeal aspirates  
896 of children with acute respiratory tract infection. *J. Clin. Virol.* **69**, 190–196  
897 (2015).
- 898 38. Bouzas, M. L. *et al.* Diagnostic accuracy of digital RNA quantification versus real-  
899 time PCR for the detection of respiratory syncytial virus in nasopharyngeal  
900 aspirates from children with acute respiratory infection. *J. Clin. Virol.* **106**, 34–40  
901 (2018).
- 902 39. Fukutani, K. F. *et al.* In situ immune signatures and microbial load at the  
903 nasopharyngeal interface in children with acute respiratory infection. *Front.*  
904 *Microbiol.* **9**, (2018).
- 905 40. Hildebrand, F., Tadeo, R., Voigt, A. Y., Bork, P. & Raes, J. LotuS: An efficient and  
906 user-friendly OTU processing pipeline. *Microbiome* **2**, 30 (2014).
- 907 41. Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina  
908 amplicon data. *Nat. Methods* **13**, 581–583 (2016).
- 909 42. McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible  
910 Interactive Analysis and Graphics of Microbiome Census Data. *PLoS One* **8**,  
911 e61217 (2013).
- 912 43. Davis, N. M., Proctor, Di. M., Holmes, S. P., Relman, D. A. & Callahan, B. J. Simple  
913 statistical identification and removal of contaminant sequences in marker-gene  
914 and metagenomics data. *Microbiome* **6**, 226 (2018).
- 915 44. Oksanen, J. *et al.* vegan: Community Ecology Package. (2019).
- 916 45. Gloor, G. B., Wu, J. R., Pawlowsky-Glahn, V. & Egozcue, J. J. It's all relative:  
917 analyzing microbiome data as compositions. *Ann. Epidemiol.* **26**, 322–329  
918 (2016).
- 919 46. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and  
920 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 921 47. Pagès, H., Aboyoun, P., Gentleman, R. & DebRoy, S. Biostrings: Efficient  
922 manipulation of biological strings. (2019).
- 923 48. Kassambara, A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests.  
924 (2020).
- 925 49. Wright, E. S. *Using DECIPHER v2.0 to Analyze Big Biological Sequence Data in R.*
- 926 50. Gregory, A. C. *et al.* Marine DNA Viral Macro- and Microdiversity from Pole to  
927 Pole. *Cell* **177**, 1109–1123.e14 (2019).
- 928 51. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for  
929 Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
- 930 52. Cantu, V. A., Sadural, J. & Edwards, R. PRINSEQ++, a multi-threaded tool for fast  
931 1 and efficient quality control and 2 preprocessing of sequencing datasets.  
932 (2019). doi:10.7287/peerj.preprints.27553v1
- 933 53. Dobin, A. *et al.* STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–  
934 21 (2013).
- 935 54. Ondov, B. D. *et al.* Mash Screen: high-throughput sequence containment

- 936 estimation for genome discovery. *Genome Biol.* **20**, 232 (2019).  
937 55. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic  
938 RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).  
939 56. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell  
940 transcriptomic data across different conditions, technologies, and species. *Nat.*  
941 *Biotechnol.* **36**, 411–420 (2018).  
942 57. Ebbert, D. *chisq.posthoc.test: A Post Hoc Analysis for Pearson’s Chi-Squared*  
943 *Test for Count Data.* (2019).  
944


**Figure 1**

# Figure 2




# Figure 3


**a**




**b**




**c**




**d**



**e**



**f**





	<b>Upper respiratory tract (swabs)</b>	<b>Lower respiratory tract (BAL)</b>
<b>Number of patients</b>	58	35
<b>COVID-19 positive (%)</b>	58 (100%)	22 (62.9%)
<b>Age (range)</b>	61.2 (37-83)	64.1 (45-85)
<b>Female sex (%)</b>	13 (22.4%)	12 (34.3%)
<b>BMI (range)</b>	28.9 (22-46.7)	26.2 (16-36.4)
<b>Diabetic (%)</b>	12 (20.7%)	6 (17.1%)
<b>Days in ICU (range)</b>	21.4 (2-72)	NA
<b>Days in hospital (range)</b>	32.5 (6-86)	NA

**Table 1. Patient demographics of our upper and lower respiratory tract cohorts**